TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02638246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered, Incentive-based intervention + Motivational Interviewing
Description: Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered, non-contingent incentives + Motivational Interviewing
Study: NCT00662155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: sedative-hypnotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: sedative-hypnotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: sedative-hypnotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: sedative-hypnotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo
Study: NCT01797523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablet by mouth once daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily in a 28 day cycle.
Study: NCT04285528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetia Fentanyl and Propofol
Description: Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PFK
Description: A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
Study: NCT03166800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinone
Description: This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT03166800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinone
Description: This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
Study: NCT03575585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment plus feedback report
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counselor Training
Description: 2 hours of training on how to use the BEST patient feedback report

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counselor Training
Description: 2 hours of training on how to use the BEST patient feedback report

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counselor Training
Description: Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counselor Training
Description: Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
Study: NCT03612232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib-s-malate
Description: oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
Study: NCT03257956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reference group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study: NCT03166800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
Study: NCT00520026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00907907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil Tablet 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept® Tablets
Description: CellCept® Tablets, 500 mg
Study: NCT01955200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: (ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: (ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: (ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
Study: NCT00641134

Intervention type: OTHER
Group type: OTHER
Intervention: A: Home-Based exercise after Cardiac Rehabilitation
Description: Home-Based exercise program,after CR, with reinforcement sessions
Study: NCT01152827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn
Study: NCT02158741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visits and Lifestyle Education Support
Study: NCT02595944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study: NCT06167122

Intervention type: PROCEDURE
Intervention: Craniofacial reconstruction
Description: Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted.
Study: NCT01777711

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting- Individual
Description: Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting- Couple
Description: Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
Study: NCT03437265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLENVU powder for oral solution
Description: PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
Study: NCT03289845

Intervention type: DEVICE
Group type: OTHER
Intervention: BHX implant (Bone anchored hearing system)
Description: Bone anchored hearing system for hearing rehabilitation
Study: NCT02656186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-intervention
Description: First 2-weeks : keeping routine dietary habit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement
Description: Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
Study: NCT00570609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Anytime education
Description: After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
Study: NCT03787641

Intervention type: DRUG
Group type: OTHER
Intervention: Protamine Sulfate
Description: Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
Study: NCT04158245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine PET Scan
Description: The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
Study: NCT00695162

Intervention type: OTHER
Group type: OTHER
Intervention: quiet
Description: no noise

Intervention type: OTHER
Group type: OTHER
Intervention: quiet
Description: no noise

Intervention type: OTHER
Group type: OTHER
Intervention: non-speech noise
Description: noise without speech

Intervention type: OTHER
Group type: OTHER
Intervention: non-speech noise
Description: noise without speech

Intervention type: OTHER
Group type: OTHER
Intervention: speech noise
Description: noise with speech present

Intervention type: OTHER
Group type: OTHER
Intervention: speech noise
Description: noise with speech present
Study: NCT00727480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
Study: NCT02892747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program
Study: NCT04102085

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02138539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal depigmenting agent (Epionce)
Description: A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone
Description: Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
Study: NCT03953287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: A randomized, cross over design
Study: NCT00742547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
Study: NCT01727947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSOME
Description: A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied \> 13% of nuclear area) in each sample will be assessed.
Study: NCT04070547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
Study: NCT01666262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine A/17/CA/2009/38 (H1N1)
Description: Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:Stabilizer
Description: 5% sucrose
Study: NCT01045681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Velcade and Dexamethasone
Description: Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
Study: NCT04028180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: p-Menthane,3-8-diol (PMD) Topical Repellent
Description: p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picaridin Topical Repellent
Description: Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human.
Study: NCT02083328

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Mannitol)
Description: Mannitol filled in gelatine capsules
Study: NCT00966589

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laparoscopic hernioplasty (TEP)
Description: Insertion of polypropylene mesh behind pubic bone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic hernioplasty (TEP)
Description: Insertion of polypropylene mesh behind pubic bone
Study: NCT03019549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study: NCT04512586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conduction System pacing and AV node ablation
Description: See study arm description.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation by pulmonary vein isolation
Description: See study arm description
Study: NCT03720691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS Supplementary motor area
Description: There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Supplementary motor area
Description: There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
Study: NCT04456881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with patellar dislocation undergo patellar femoral medial reconstruction
Description: Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
Study: NCT04979663

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Description: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
Study: NCT03019549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally
Study: NCT05366608

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6
Description: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6
Description: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
Study: NCT01959360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral
Description: Total hip replacement; direct lateral approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive
Description: Total hip replacement; minimal invasive approach
Study: NCT03122535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 70 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 70 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 110 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 110 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.